Drug profile

The FDA adverse-event record for Flunixin Megl Topical Solution

132 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Flunixin Megl Topical Solution. See the species affected, top reactions, and outcomes below.

132
adverse-event reports
24.2%
death-coded share
Cattle
most-reported species
37
Containers, Leaking - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
132
Total Reports
32
Deaths Reported
24.2%
Death Rate

Active Ingredients

Flunixin Megl Topical Solution

Administration Routes

TopicalUnknownTransdermal

Species Affected

Cattle 81
Unknown 40
Human 5
Pig 2
Frog 2
Horse 1
Alpaca 1

Most Affected Breeds

Unknown 46
Cattle (other) 26
Crossbred Bovine/Cattle 12
Aberdeen Angus 9
Holstein-Friesian also known as Holstein 9
Cattle (unspecified) 8
Mixed (Cattle) 3
Brahman 3
Hereford cattle 2
Jersey 2

Most Reported Reactions

Containers, Leaking 37
Death 30
Lack of efficacy - NOS 22
Closure, Abnormal 22
Seal, Abnormal 18
Flaking skin 11
Application site hair loss 11
Application site blister 7
Application site skin scaling 7
Lack of efficacy (bacteria) - NOS 7
Application site burn 4
Increased skin sensitivity 3

Outcome Breakdown

Ongoing
34 (30.1%)
Died
31 (27.4%)
Recovered/Normal
24 (21.2%)
Outcome Unknown
22 (19.5%)
Euthanized
2 (1.8%)

Flunixin Megl Topical Solution Adverse Event Insights

132 reports name Flunixin Megl Topical Solution; 32 recorded a death outcome (24.2% of reported events, not a population-level mortality rate). Active ingredient: Flunixin Megl Topical Solution. Administration routes: Topical, Unknown, Transdermal.

By species: Cattle (81 reports), Unknown (40 reports), Human (5 reports). By breed: Unknown (46), Cattle (other) (26), Crossbred Bovine/Cattle (12).

Leading clinical signs: Containers, Leaking (37), Death (30), Lack of efficacy - NOS (22), Closure, Abnormal (22). Outcome, 113 coded reports: Ongoing leads at 30.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.